All Oncology News

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

A panel of experts take stock of the current standing of HER2-directed ADCs in solid tumors, including breast, gynecologic, GI, lung, and GU cancers.

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.

Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.

Sonrotoclax plus dexamethasone was well tolerated and produced early, durable responses in patients with myeloma harboring t(11:14).

Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.

Daniel J. George, MD, discusses ongoing research with radioligand therapy in prostate cancer and its potential role in novel settings and combinations.

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Cadonilimab plus chemotherapy has been approved in China for first-line locally advanced or metastatic gastric/GEJ adenocarcinoma.

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Durcabtagene autoleucel generated responses with a tolerable safety profile in relapsed/refractory multiple myeloma.

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.